digital health companies weight loss glp-1 Virtual startups: Pill mills or the future of obesity care? Noom Launches Microdose GLP-1 Program,

The FDA has flagged concerns about immunogenicity and about peptide-related impurities in unregulated products

Novo is, as ever, jostling with obesity market rival Eli Lilly

At Digestive & Liver Disease Consultants, P.A., our team of experienced gastroenterologists can help diagnose and treat a wide range of gut health conditions

In adipocytes, DPP4 inhibitors are reported to downregulate the expression of NOX4 (nicotinamide adenine dinucleotide phosphate oxidase 4, a major source of ROS) in failing heart [27, 28]

C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis